Chimeric antigen receptor T-cell (CAR-T) therapy against B-cell maturation antigen (BCMA) is a promising new treatment for multiple myeloma (MM) with high and rapid clinical efficacy even in multiply refractory patients. The gene discussed is TNFRSF17; the disease is AL amyloidosis.